交易 Innoviva - INVA CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|
Innoviva Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 331.339 | 391.866 | 336.794 | 261.016 | 261.004 |
收入 | 331.339 | 391.866 | 336.794 | 261.016 | 261.004 |
总营业费用 | -121.69 | 16.763 | 15.671 | 14.656 | 22.753 |
销售/一般/行政费用,总计 | 63.538 | 16.187 | 13.883 | 14.656 | 22.753 |
研究与开发 | 41.432 | 0.576 | 1.788 | 0 | 0 |
营业收入 | 453.029 | 375.103 | 321.123 | 246.36 | 238.251 |
利息收入(费用),非经营净值 | -162.707 | 73.799 | 33.47 | -13.12 | -22.294 |
其他,净值 | -3.373 | -3.626 | -0.348 | -0.345 | -5.702 |
税前净收入 | 286.949 | 445.276 | 354.245 | 232.895 | 210.255 |
税后净收入 | 220.262 | 368.837 | 293.814 | 190.993 | 406.328 |
未计算非常项目前的净收益 | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
非常规项目总计 | 0 | ||||
净收入 | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
普通股股东可获收益 (不含非经常性项目) | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
普通股股东可获收益 (含非經常性項目) | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
摊薄净收入 | 216.36 | 270.59 | 229.119 | 157.288 | 395.056 |
摊薄后加权平均股 | 95.248 | 94.31 | 113.554 | 113.409 | 113.408 |
扣除特别项目的每股摊薄盈利 | 2.27154 | 2.86915 | 2.01771 | 1.38691 | 3.48349 |
每股正常摊薄盈利 | 0.28877 | 2.86915 | 2.01771 | 1.38691 | 3.48349 |
少数股东权益 | -6.341 | -102.983 | -69.412 | -33.705 | -11.272 |
摊薄调整 | 2.439 | 4.736 | 4.717 | ||
收入成本,共计 | 13.793 | ||||
毛利 | 317.546 | ||||
Depreciation / Amortization | 5.581 | ||||
异常费用(收入) | -246.034 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
总收入 | 65.803 | 67.257 | 108.22 | 90.059 | 107.68 |
收入 | 65.803 | 67.257 | 108.22 | 90.059 | 107.68 |
总营业费用 | 41.622 | -221.97 | 25.666 | 32.992 | 3.153 |
销售/一般/行政费用,总计 | 17.454 | 27.81 | 11.782 | 6.492 | 3.113 |
研究与开发 | 9.985 | 11.725 | 13.884 | 5.838 | 0.04 |
营业收入 | 24.181 | 289.227 | 82.554 | 57.067 | 104.527 |
利息收入(费用),非经营净值 | -86.246 | -2.831 | -61.531 | -12.099 | -46.448 |
其他,净值 | -2.623 | 0.028 | -0.528 | -0.25 | -1.59 |
税前净收入 | -64.688 | 286.424 | 20.495 | 44.718 | 56.489 |
税后净收入 | -68.314 | 229.347 | 21.371 | 37.858 | 45.65 |
少数股东权益 | 0 | 36.176 | -20.432 | -22.085 | -35.305 |
未计算非常项目前的净收益 | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
净收入 | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
普通股股东可获收益 (不含非经常性项目) | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
普通股股东可获收益 (含非經常性項目) | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
摊薄调整 | 3.175 | 3.654 | 2.569 | 1.183 | |
摊薄净收入 | -68.314 | 268.698 | 4.593 | 18.342 | 11.528 |
摊薄后加权平均股 | 95.776 | 95.83 | 95.653 | 93.73 | 81.632 |
扣除特别项目的每股摊薄盈利 | -0.71327 | 2.8039 | 0.04802 | 0.19569 | 0.14122 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
每股正常摊薄盈利 | -0.71327 | 0.57547 | 0.04802 | 0.38231 | 0.14122 |
异常费用(收入) | 0 | -266.696 | 0 | 20.662 | |
收入成本,共计 | 10.113 | 3.68 | |||
毛利 | 55.69 | 63.577 | |||
Depreciation / Amortization | 4.07 | 1.511 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
流动资产总额 | 313.673 | 342.058 | 431.234 | 199.043 | 200.369 |
现金和短期投资 | 201.525 | 246.487 | 350.845 | 114.908 | 129.075 |
现金等价物 | 201.525 | 246.487 | 278.096 | 62.417 | 73.336 |
短期投资 | 0 | 72.749 | 52.491 | 55.739 | |
应收账款总额,净额 | 110.711 | 93.931 | 79.427 | 83.286 | 70.54 |
Accounts Receivable - Trade, Net | 110.711 | 93.931 | 79.427 | 83.286 | 70.54 |
Prepaid Expenses | 1.437 | 1.64 | 0.962 | 0.849 | 0.754 |
Total Assets | 926.395 | 999.57 | 724.826 | 548.193 | 367.337 |
Property/Plant/Equipment, Total - Net | 0.012 | 0.028 | 0.033 | 0.16 | 0.209 |
Intangibles, Net | 111.43 | 125.253 | 139.076 | 152.899 | 166.722 |
Other Long Term Assets, Total | 17.435 | 93.973 | 154.483 | 196.091 | 0.037 |
Total Current Liabilities | 5.807 | 6.11 | 5.371 | 5.7 | 34.742 |
Accounts Payable | 0.027 | 0.066 | 0.01 | 0.011 | 0.601 |
Accrued Expenses | 5.78 | 6.044 | 5.361 | 5.689 | 9.141 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 25 | |||
Other Current Liabilities, Total | 0 | ||||
Total Liabilities | 511.652 | 459.658 | 411.331 | 394.61 | 610.196 |
Total Long Term Debt | 394.653 | 385.517 | 377.12 | 382.855 | 574.362 |
Long Term Debt | 394.653 | 385.517 | 377.12 | 382.855 | 574.362 |
Other Liabilities, Total | 0 | 0.106 | 0.219 | 0.586 | 0.94 |
Total Equity | 414.743 | 539.912 | 313.495 | 153.583 | -242.859 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.696 | 1.014 | 1.013 | 1.011 | 1.019 |
Additional Paid-In Capital | 1264.02 | 1260.9 | 1258.86 | 1256.27 | 1258.15 |
Retained Earnings (Accumulated Deficit) | -456.148 | -722.002 | -946.404 | -1103.69 | -1498.75 |
Treasury Stock - Common | -393.829 | 0 | -3.263 | ||
Other Equity, Total | 0 | 0.027 | -0.003 | -0.018 | |
Total Liabilities & Shareholders’ Equity | 926.395 | 999.57 | 724.826 | 548.193 | 367.337 |
Total Common Shares Outstanding | 69.5655 | 101.392 | 101.288 | 101.098 | 101.896 |
Minority Interest | 111.192 | 67.925 | 28.621 | 5.469 | 0.152 |
Long Term Investments | 483.845 | 438.258 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 317.823 | 313.673 | 236.928 | 148.261 | 372.933 |
现金和短期投资 | 216.802 | 201.525 | 135.115 | 43.265 | 282.89 |
现金等价物 | 216.802 | 201.525 | 135.115 | 43.265 | 282.89 |
应收账款总额,净额 | 93.515 | 110.711 | 101.271 | 104.262 | 88.974 |
Accounts Receivable - Trade, Net | 93.515 | 110.711 | 101.271 | 104.262 | 88.974 |
Prepaid Expenses | 5.576 | 1.437 | 0.542 | 0.734 | 1.069 |
Total Assets | 1107.47 | 926.395 | 887.239 | 789.15 | 1088.29 |
Property/Plant/Equipment, Total - Net | 3.985 | 0.012 | 0.015 | 0.019 | 0.024 |
Intangibles, Net | 212.974 | 111.43 | 114.885 | 118.341 | 121.797 |
Long Term Investments | 544.437 | 483.845 | 507.116 | 473.677 | 519.325 |
Other Long Term Assets, Total | 22.711 | 17.435 | 28.295 | 48.852 | 74.211 |
Total Current Liabilities | 109.227 | 5.807 | 3.125 | 5.371 | 3.804 |
Accounts Payable | 1.808 | 0.027 | 0.089 | 0.03 | 0.014 |
Accrued Expenses | 11.403 | 5.78 | 3.036 | 5.341 | 3.79 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 720.832 | 511.652 | 484.428 | 459.37 | 453.829 |
Total Long Term Debt | 442.731 | 394.653 | 392.295 | 389.989 | 387.728 |
Long Term Debt | 442.731 | 394.653 | 392.295 | 389.989 | 387.728 |
Minority Interest | 165.575 | 111.192 | 88.994 | 63.965 | 62.22 |
Other Liabilities, Total | 3.299 | 0 | 0.014 | 0.045 | 0.077 |
Total Equity | 386.642 | 414.743 | 402.811 | 329.78 | 634.461 |
Common Stock | 0.696 | 0.696 | 0.695 | 0.695 | 1.014 |
Additional Paid-In Capital | 1182.91 | 1264.02 | 1262.44 | 1261.84 | 1261.33 |
Retained Earnings (Accumulated Deficit) | -403.137 | -456.148 | -466.493 | -538.931 | -627.879 |
Total Liabilities & Shareholders’ Equity | 1107.47 | 926.395 | 887.239 | 789.15 | 1088.29 |
Total Common Shares Outstanding | 69.594 | 69.5655 | 69.492 | 69.495 | 101.408 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Treasury Stock - Common | -393.829 | -393.829 | -393.829 | -393.829 | |
Other Current Assets, Total | 1.93 | ||||
Goodwill, Net | 5.544 | ||||
Current Port. of LT Debt/Capital Leases | 96.016 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
净收入/起跑线 | 368.837 | 293.814 | 190.993 | 406.328 | 134.272 |
经营活动产生的现金 | 363.813 | 313.113 | 257.458 | 223.531 | 141.749 |
经营活动产生的现金 | 13.832 | 13.84 | 13.874 | 13.872 | 13.982 |
非现金物品 | -78.415 | -40.639 | 7.621 | 16.145 | 21.775 |
已付现金利息 | 9.933 | 9.933 | 10.974 | 17.861 | 40.353 |
营运资金的变化 | -16.873 | -14.322 | 3.095 | -16.76 | -28.28 |
投资活动产生的现金 | 43.722 | -314.937 | -18.003 | 3.519 | -23.236 |
资本支出 | 0 | -0.013 | -0.012 | 0 | 0 |
其他投资现金流量项目,总计 | 43.722 | -314.924 | -17.991 | 3.519 | -23.236 |
融资活动产生的现金 | -452.497 | -29.785 | -23.776 | -237.969 | -163.193 |
融资现金流项目 | -59.457 | -30.129 | -10.553 | -5.955 | 0.023 |
Total Cash Dividends Paid | 0 | 0 | -0.011 | -0.08 | -0.281 |
股票的发行(报废),净额 | -393.04 | 0.344 | 0.538 | -1.934 | -99.193 |
债务的发行(退还),净额 | 0 | 0 | -13.75 | -230 | -63.742 |
现金净变化 | -44.962 | -31.609 | 215.679 | -10.919 | -44.68 |
Deferred Taxes | 76.432 | 60.42 | 41.875 | -196.054 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 37.858 | 368.837 | 323.187 | 220.541 | 109.695 |
Cash From Operating Activities | 98.102 | 363.813 | 265.432 | 168.721 | 84.107 |
Cash From Operating Activities | 3.501 | 13.832 | 10.376 | 6.918 | 3.46 |
Deferred Taxes | 6.86 | 76.432 | 65.6 | 45.069 | 19.736 |
Non-Cash Items | 31.684 | -78.415 | -124.495 | -93.637 | -52.003 |
Cash Interest Paid | 5.411 | 9.933 | 9.933 | 4.967 | 4.967 |
Changes in Working Capital | 18.199 | -16.873 | -9.236 | -10.17 | 3.219 |
Cash From Investing Activities | -143.156 | 43.722 | 63.627 | 63.627 | -26.394 |
Capital Expenditures | -0.009 | 0 | 0 | 0 | 0 |
Other Investing Cash Flow Items, Total | -143.147 | 43.722 | 63.627 | 63.627 | -26.394 |
Cash From Financing Activities | 60.331 | -452.497 | -440.431 | -435.57 | -21.31 |
Financing Cash Flow Items | -6.507 | -59.457 | -46.358 | -41.446 | -21.285 |
Issuance (Retirement) of Stock, Net | 0.214 | -393.04 | -394.073 | -394.124 | -0.025 |
Net Change in Cash | 15.277 | -44.962 | -111.372 | -203.222 | 36.403 |
Total Cash Dividends Paid | 0 | ||||
Issuance (Retirement) of Debt, Net | 66.624 | 0 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 14.3359 | 9766472 | 318524 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.3365 | 7041846 | 54802 | 2022-12-31 | LOW |
Sarissa Capital Management, L.P. | Hedge Fund | 9.7085 | 6614000 | 0 | 2022-12-31 | LOW |
Putnam Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 7.3406 | 5000852 | 49183 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 6.2085 | 4229607 | -36066 | 2022-12-31 | HIGH |
Westfield Capital Management Company, L.P. | Investment Advisor/Hedge Fund | 6.0273 | 4106136 | 145968 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 4.7077 | 3207194 | 271075 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.3086 | 2253988 | -216906 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 3.1327 | 2134156 | -369816 | 2022-12-31 | HIGH |
Systematic Financial Management, L.P. | Investment Advisor | 2.8675 | 1953525 | 114784 | 2022-12-31 | LOW |
Assenagon Asset Management S.A. | Investment Advisor | 2.5143 | 1712874 | -190058 | 2022-12-31 | HIGH |
LSV Asset Management | Investment Advisor | 2.4093 | 1641361 | -1120342 | 2022-12-31 | LOW |
Pacer Advisors, Inc. | Investment Advisor | 2.2585 | 1538654 | 63256 | 2022-12-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7568 | 1196821 | 46886 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.4466 | 985539 | 147595 | 2022-12-31 | HIGH |
D. E. Shaw & Co., L.P. | Hedge Fund | 1.4372 | 979124 | 46803 | 2022-12-31 | MED |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.045 | 711936 | 164118 | 2022-12-31 | LOW |
BofA Global Research (US) | Research Firm | 0.9805 | 667991 | -8277 | 2022-12-31 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.9348 | 636816 | -350775 | 2022-12-31 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.9296 | 633331 | 25245 | 2022-12-31 | LOW |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Innoviva Company profile
关于 Innoviva
Innoviva, Inc.是一家拥有特许权使用费和其他医疗保健资产组合的公司。 其特许权使用费组合包括与葛兰素集团有限公司(GSK)合作的呼吸系统资产,包括RELVAR/BREO ELLIPTA(糠酸氟替卡松/维兰特罗,FF/VI)、ANORO ELLIPTA(UMEClidinium bromide/维兰特罗,UMEC/VI)和TRELEGY ELLIPTA(FF/UMEC/VI组合)。 根据长效β2受体激动剂(LABA)合作协议,Innoviva有权从葛兰素史克公司获得RELVAR/BREO ELLIPTA的销售版税以及ANORO和ELLIPTA的销售版税。 RELVAR/BREO是一种每日一次的组合药物,由LABA、维兰特罗(VI)和吸入性皮质类固醇(ICS)以及糠酸氟替卡松(FF)组成。 ANORO ELLIPTA是由长效毒蕈碱拮抗剂(LAMA)、UMEC溴化铵(UMEC)和LABA(VI)组成的每日一次的药物。 TRELEGY ELLIPTA是一种由ICS、LAMA和LABA组成的每日一次的复合药。
Industry: | Pharmaceuticals (NEC) |
1350 Old Bayshore Highway
Suite 400
94010
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。